Last Updated : April 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Zevalin | Ibritumomab tiuxetan | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Zytiga (Resubmission) | Abiraterone | Prostate Cancer Resubmission | Withdrawn | |||
| TBD | Entrectinib | Withdrawn | ||||
| Kynmobi | apomorphine hydrochloride | Parkinson’s Disease | Withdrawn | |||
| TBD | Bevacizumab | Cancelled | ||||
| Imbruvica | Ibrutinib | |||||
| TBD | Rituximab | Cancelled | ||||
| Translarna | ataluren | Cancelled | ||||
| Atriance | Nelarabine | Cancelled | ||||
| TBC | ravulizumab | Paroxysmal nocturnal hemoglobinuria. | Withdrawn |
Last Updated : April 20, 2024